Forest Lexapro Approval Includes Label Claim Of Greater Potency Than Celexa
Executive Summary
Forest's Lexapro (escitalopram) label includes a statement of greater potency than its predecessor antidepressant Celexa (citalopram)
You may also be interested in...
Forest Expects Lexapro To Lead Market By ’05; Will Re-Launch In GAD In ’04
Forest expects its anti-depressant Lexapro (escitalopram) to lead the selective serotonin reuptake inhibitor market by 2005
Forest Expects Lexapro To Lead Market By ’05; Will Re-Launch In GAD In ’04
Forest expects its anti-depressant Lexapro (escitalopram) to lead the selective serotonin reuptake inhibitor market by 2005
Forest Lexapro maintenance claim
Forest Lexapro receives supplemental approval for prevention of relapse following long-term treatment of major depressive disorder Aug. 29. Escitalopram longer-term efficacy data will replace data from the predecessor antidepressant Celexa (citalopram) in Lexapro's Aug. 14 approved labeling (1"The Pink Sheet" Aug. 19, p. 3). The sNDA was filed Oct. 29, seven months after the NDA was filed...